Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Cameron J. Turtle, Ryan D. Cassaday et al.|Blood|2020Cited by 217
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Cameron J. Turtle, Emily C. Liang et al.|Blood Advances|2025Cited by 10
Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALLJordan Gauthier, Cameron J. Turtle, Nicolas Gazeau et al.|Transplantation and Cellular Therapy|2023Cited by 1
Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow CytometryDelaney R. Kirchmeier, Cameron J. Turtle, Alyssa Sheih et al.|Blood|2021Cited by 1
Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II StudyNicolas Gazeau, Jordan Gauthier, Salvatore Fiorenza et al.|Transplantation and Cellular Therapy|2023Cited by 1